DIABLO 2 version 1

  • Research type

    Research Study

  • Full title

    Point of care diagnosis of gastrointestinal disease using laser spectroscopy (DIABLO 2)

  • IRAS ID

    263305

  • Contact name

    Christopher Walton

  • Contact email

    c.walton@cranfield.ac.uk

  • Sponsor organisation

    Cranfield University

  • Clinicaltrials.gov Identifier

    WVA3007N, Budget code

  • Duration of Study in the UK

    1 years, 2 months, days

  • Research summary

    We will investigate Clostridium difficile infection (CDI), a bowel infection producing catastrophic diarrhoea and which can prove fatal, especially in the elderly and others with a poor immune response. It has been estimated that 3-5% of the population carry C. difficile bacteria without suffering any ill effects, and this makes management of the disease in hospitals difficult.

    Current tests for CDI use traditional laboratory "wet chemistry" methods, with limited diagnostic performance and a lead time measured in hours. Delayed diagnosis can lead to patients being unnecessarily isolated from wards or treated unnecessarily with antibiotics, which contributes to the development of antimicrobial resistance.

    Nurses report being able to detect an outbreak of CDI on a ward by the presence of a characteristic smell, and microbiologists are able to smell the difference between different bacteria grown in culture. Variation in the levels of volatile organic compounds (VOCs) emitted from a range of human samples (e.g. breath, blood, urine) are known to be associated with metabolic status and have been linked to particular diseases. In an earlier study, we found several VOCs produced by faeces which were associated with a diagnosis of CDI. We now want to expand and refine our earlier work by using an increased number of samples which will allow us to establish the applicability of our findings across different age and gender groups. In doing so, we will use actual clinical samples which have been referred to a chemical pathology laboratory for CDI testing. This will allow us to test the validity of our approach using a realistic sample stream.

    This is part of a larger study in which we are developing a laser-based instrument to measure faecal VOCs with the ultimate aim of enabling CDI diagnosis at the bedside within minutes.

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    19/LO/1505

  • Date of REC Opinion

    4 Oct 2019

  • REC opinion

    Favourable Opinion